



THE
BLADDER CANCER
COMPANY

Photocure ASA: Notification of primary insider transaction

Oslo, Norway, 3 December 2024: Board member Ghizlane Tagmouti has on 2 December 2024 acquired 20,218 shares at an average price of NOK 50.186. Primary insider notification pursuant to the market abuse regulation article 19 is attached.

For further information, please contact:

Photocure CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading Act.